Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 4,743

Document Document Title
WO/2021/058024A1
Provided are a class of heterospirocyclic compound which act as a lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in the preparation of a drug for treating diseases associated with LSD1. The heterospirocyclic compounds ...  
WO/2021/050702A1
Provided herein are compounds that inhibit histone lysine demethylase (KDM) and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs ther...  
WO/2021/038490A1
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3 ...  
WO/2021/033729A1
[Problem] The present invention addresses the problem of providing: a compound having an improved balance of agonistic activity to S1P5 receptors in relation to S1P1 receptors; and forms of the compound that are suitable for serving as a...  
WO/2021/022890A1
The present invention belongs to the technical field of biomedicine, and specifically relates to a cyclohexanamine D3/D2 receptor partial agonist and a pharmaceutically acceptable salt thereof, and a synthetic method therefor and use the...  
WO/2021/026179A1
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...  
WO/2021/018826A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlling...  
WO/2021/020429A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.  
WO/2021/018833A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, k and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for c...  
WO/2021/009232A1
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlli...  
WO/2021/009568A1
Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and f...  
WO/2021/007663A1
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...  
WO/2020/259366A1
Disclosed are a crystal form of a coagulation factor XIa inhibitor and a preparation method therefor, wherein the X-ray powder diffraction pattern of the crystal form comprises diffraction peaks of the 2θ angle at 6.9±0.2°, 15.9±0.2...  
WO/2020/234423A1
The presented invention relates to salts of Siponimod with Fumaric acid (1:1) and solid Forms 1 and 2 thereof. The presented invention further relates to salts of Siponimod with Maleic acid (1:1) and solid Forms 1, 2, 3, 4, 5, 6, 7, 8 an...  
WO/2020/219258A1
Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable az...  
WO/2020/219876A1
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...  
WO/2020/174408A9
The present application provides novel polymorphic forms of siponimod, their processes, their use in purification of other crystalline polymorphic forms of siponimod, and pharmaceutical compositions containing them. The present applicati...  
WO/2020/208167A1
The present invention relates to solid Form 1, Form 2, Form 3 and Form 6 of the compound Siponimod and processes for preparation thereof. The present invention further relates to processes for preparation of solid Form A of the compound ...  
WO/2020/210246A1
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical composi...  
WO/2020/206594A1
Described are 1, 2, 4-substituted azetidine compounds of formula I, as well as pharmaceutical compositions and dosage forms comprising the compounds, and their use as a medicament. The compounds may find use as antibacterial agents, in p...  
WO/2020/203610A1
Provided is a medicinal drug for treating or preventing rheumatoid arthritis. As a medicinal drug for treating or preventing rheumatoid arthritis, the present invention uses, as an active ingredient, a compound that has an effect of bloc...  
WO/2020/201172A1
The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.  
WO/2020/203609A1
Provided is a medicinal drug for treating or preventing pruritus. As a medicinal drug for treating or preventing pruritus, the present invention uses, as an active ingredient, a compound that has an effect of blocking the Cav3.2 T-type c...  
WO/2020/193419A1
The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.  
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/180624A1
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function ...  
WO/2020/173016A1
The present invention relates to a resorcinol dianisole derivative, wherein the chemical structure of this compound is as represented by the following formula (I). The compound of the present invention can inhibit the binding of programm...  
WO/2020/173346A1
The present invention relates to the pharmaceutical and chemical field, and provided is a method for preparing siponimod. The method of the present invention relates to taking 3-bromo-4-methylacetophenone as a starting material, and perf...  
WO/2020/174408A1
The present application provides novel polymorphic forms of siponimod, their processes, their use in purification of other crystalline polymorphic forms of siponimod, and pharmaceutical compositions containing them. The present applicati...  
WO/2020/175392A1
A compound which has a molecular weight of 3,000 or less, while having a partial structure that is represented by formula (X). (In formula (X), ring W1 represents a ring structure that does not have aromaticity, while having at least one...  
WO/2020/175393A1
A compound represented by general formula (I). [In formula (I), R3, R4, and R5 each independently represent an electron-attracting group. R1, R2, R6, and R7 each independently represent a hydrogen atom, a heterocyclic group, a halogen at...  
WO/2020/161632A1
The present application provides novel polymorphic forms of siponimod, their processes, their use in purification of other crystalline polymorphic forms of siponimod, and pharmaceutical compositions containing them. The present applicati...  
WO/2020/156359A1
Disclosed in the present invention are a quaternary ammonium salt compound and a preparation method therefor and a use thereof, relating to the field of medicinal chemistry. Disclosed in the present invention is the compound shown in for...  
WO/2020/159824A1
Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.  
WO/2020/154250A1
Disclosed is method for converting a beta-lactam antibiotic into a "masked" beta- lactam antibiotic to permit it to cross the waxy cuticle of a plant and then subsequently unmasking the beta-lactam and converting it into an active beta-l...  
WO/2019/231933A3
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.  
WO/2020/146568A1
A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclizatio...  
WO/2020/142742A1
Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.  
WO/2020/114477A1
The present invention relates to a compound represented by the formula (II), the pharmaceutically acceptable salt thereof, and the uses of the compound acting as an S1P1 agonist.  
WO/2020/118041A1
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...  
WO/2020/109434A1
The present invention relates to compounds of formula (I), to processes for producing the compounds, and to electronic devices containing at least one compound of formula (I).  
WO/2020/103884A1
Amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed ...  
WO/2020/104930A1
The present invention relates to an improved asymmetric synthesis of azaspiro or di- azaspiro compound (hereafter referred to as the compound 5, (5A) or (5N)) or their pharmaceutically acceptable salts and derivatives; through the format...  
WO/2020/104822A1
The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is...  
WO/2020/098710A1
Provided in the present application are a substituted bis-aryl amide compound and a preparation method and an application therefor, the substituted bis-aryl amide compound or a pharmaceutically acceptable salt thereof having the structur...  
WO/2020/080979A1
This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, me...  
WO/2020/074489A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...  
WO/2020/039092A3
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039088A3
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/056553A1
The invention belongs to the field of organic chemistry, and particularly relates to a method for preparing a heterocyclic compound represented by formula I and salts thereof. Compared with the prior art, the invention avoids the use of ...  

Matches 1 - 50 out of 4,743